<DOC>
	<DOCNO>NCT00064636</DOCNO>
	<brief_summary>The purpose study evaluate safe VELCADE ( PS-341 ) give Taxotere ( Docetaxel ) patient non-small cell lung cancer solid tumor , also see effect ( good bad ) cancer .</brief_summary>
	<brief_title>Phase I Dose Escalation Study VELCADE Plus Docetaxel Patients With Advanced Non-Small Cell Lung Cancer Other Solid Tumors</brief_title>
	<detailed_description>This dose escalation study , mean first group patient enter study receive low dose VELCADE Docetaxel . If low dose VELCADE Docetaxel appear safe , next group patient receive high dose VELCADE docetaxel .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Adults advance and/or metastatic NSCLC solid tumor treatmentnaïve previously receive two antineoplastic treatment regimen know curative therapy may enrol study . The actual number patient enrol depends dose cohort doselimiting toxicity see . Inclusion criterion Each patient must meet follow inclusion criterion enrol study : Patient histologicallyconfirmed advanced and/or metastatic NSCLC solid tumor , patient treatmentnaïve previously receive two antineoplastic treatment regimen know curative therapy . Patients enrol Low High Dose Expanded Cohorts must diagnosis NSCLC order eligible . Previous treatment carboplatin paclitaxel preclude enrollment study . Patient measurable evaluable disease . Patients enrol expanded cohort must measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) guideline [ 1 ] present Table 3 Table 4 . Patient 18 year age old . Patient Karnofsky performance status 60 % high . Patient life expectancy three month longer . Patient follow pretreatment laboratory data within 21 day first study drug dose : Absolute neutrophil count ( ANC ) great equal 1,500/mm3 . Platelet count great equal 100,000/mm3 . Hemoglobin great equal 8.0 g/dL . Serum creatinine less equal 1.5 x ULN : Patient give voluntary write informed consent performance studyrelated procedure part normal medical care . Female patient postmenopausal , surgically sterilize , willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) Screening visit 90 day last study drug dose . Male patient agree use acceptable barrier method contraception Screening visit 90 day last study drug dose . Exclusion criteria Patients meet follow exclusion criterion enrol study . Patient previously receive treatment docetaxel . Patient previously receive treatment cisplatin cumulative dose &gt; 350 mg/m2 . Patient receive chemotherapy within four week , nitrosoureas within six week , antibody therapy within eight week enrollment . Patient receive radiation therapy within four week enrollment . Patient history radiation therapy &gt; 25 % bone marrow . Patient recover toxic effect previous chemotherapy radiation antibody therapy . Patient major surgery within four week enrollment . Patient history allergic reaction appropriate diuretic antiemetic administer conjunction study drug . Patient history severe hypersensitivity reaction docetaxel agent formulate polysorbate 80 . Patient electrocardiographic evidence acute ischemia new conduction system abnormality . Patient myocardial infarction within six month enrollment . Patient uncontrolled brain metastasis central nervous system disease . Patients control brain metastasis receive corticosteroid anticonvulsant eligible study enrollment . Patient Grade 2 high peripheral neuropathy Patient leukemia lymphoma . Patient follow pretreatment laboratory data within 21 day first study drug dose : Total bilirubin &gt; upper limit normal ( ULN ) . Alanine transaminase ( ALT ) and/or aspartate transaminase ( AST ) &gt; 1.5 x ULN concurrent alkaline phosphatase &gt; 2.5 x ULN . Patient HIVinfected . Patient hepatitis B surface antigen positive previously document hepatitis C Patient uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . Patient another serious medical psychiatric illness could , investigator ’ opinion , potentially interfere completion treatment accord protocol . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
</DOC>